Dempze Nancy E Gilead Sciences, Inc. Transaction History

Dempze Nancy E

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Jan 24, 2019	SELL	$60.54 - $79.0 $315,413 - $411,590	-5,210 Closed	0 $0
Q3 2018 Oct 15, 2018	SELL	$71.28 - $78.92 $210,703 - $233,287	-2,956 Reduced 36.2%	5,210 $402,000
Q2 2018 Jul 30, 2018	BUY	$64.88 - $75.68 $38,798 - $45,256	598 Added 7.9%	8,166 $579,000
Q1 2018 Apr 24, 2018	BUY	$72.84 - $88.8 $6,045 - $7,370	83 Added 1.11%	7,568 $570,000
Q4 2017 Feb 02, 2018	SELL	$71.15 - $83.52 $7,328 - $8,602	-103 Reduced 1.36%	7,485 $536,000
Q3 2017 Oct 26, 2017	BUY	$72.11 - $85.47 $547,170 - $648,546	7,588	7,588 $615,000

1,924

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Dempze Nancy E, based on Form 13F filings with the SEC.

Stay updated on Dempze Nancy E with notifications on news.